NCT06960577
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06960577
Title Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Acronym NIAGARA-2
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD | ITA | FRA | ESP | CAN | BRA | AUS


No variant requirements are available.